References Product warnings updated for GLP-1 RA class, 01 December 2025, Therapeutic Good Administrations, GLP-1 RAs: warnings aligned over potential risk of suicidal thoughts or behaviours, 01 December 2025, Therapeutic Good Administration, Updated contraception advice for Mounjaro (tirzepatide), 01 December 2025, Therapeutic Good Administrations, GLP-1 medicines for weight loss and diabetes: what you need to know, 20 August 2025, Medicine and Healthcare Product Regulatory Agency, Australias drug regulator issues mental health warning for weight-loss drugs including Ozempic, 01 December 2025,
Metabolic Research Compounds Hub Research compounds investigated in preclinical models of metabolic function
Stevens-Johnson syndrome is another serious reaction
doi: 10.1126/science.1070477 56 MakkerJ.ChilimuriS.BellaJ
The FDA declared the shortage resolved in February 2025, triggering countdown clocks at every compounding facility in America